One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK

References

• McIntoshRLRogersSLLimLNatural history of central retinal vein occlusion: an evidence-based systematic reviewOphthalmology2010117611131123.e1520430446
   PubMed Web of Science ®Google Scholar
• MitchellPSmithWChangAPrevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye StudyArch Ophthalmol1996114124312478859084
   PubMed Web of Science ®Google Scholar
• RogersSMcIntoshRLCheungNThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology2010117231331920022117
   PubMed Web of Science ®Google Scholar
• The Royal College of OphthalmologyInterim guidelines for management of retinal vein occlusion Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdfAccessed July 17, 2015
   Google Scholar
• BrownDMCampochiaroPASinghRPCRUISE InvestigatorsRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology201011761124113320381871
   PubMed Web of Science ®Google Scholar
• VarmaRBresslerNMSuñerIBRAVO and CRUISE Study GroupsImproved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trialsOphthalmology2012119102108211822817833
   PubMed Web of Science ®Google Scholar
• HeierJSCampochiaroPAYauLRanibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trialOphthalmology2012119480280922301066
   PubMed Web of Science ®Google Scholar
• CampochiaroPASophieRPearlmanJRETAIN Study GroupLong-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN studyOphthalmology2014121120921924112944
   PubMed Web of Science ®Google Scholar
• OguraYRoiderJKorobelnikJFGALILEO Study GroupIntravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO studyAm J Ophthalmol201415851032103825068637
   PubMed Web of Science ®Google Scholar
• HeierJSClarkWLBoyerDSIntravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS studyOphthalmology201412171414142024679444
   PubMed Web of Science ®Google Scholar
• HallerJABandelloFBelfortRJrOzurdex GENEVA Study GroupDexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study resultsOphthalmology2011118122453246021764136
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceDexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusionNICE technology appraisal guidanceTA22972011 Available from: https://www.nice.org.uk/guidance/ta229Accessed July 17, 2015
   Google Scholar
• National Institute for Health and Care ExcellenceRanibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionNICE technology appraisal guidanceTA28352013 Available from: https://www.nice.org.uk/guidance/ta283Accessed July 17, 2015
   Google Scholar
• National Institute for Health and Care ExcellenceAflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionNICE technology appraisal guidanceTA30522014 Available from: https://www.nice.org.uk/guidance/ta305Accessed July 17, 2015
   Google Scholar
• WuLMartínez-CastellanosMAQuiroz-MercadoHPan American Collaborative Retina Group (PACORES)Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)Graefes Arch Clin Exp Ophthalmol20082461818717674014
   PubMed Web of Science ®Google Scholar
• RabenaMDPieramiciDJCastellarinAANasirMAAveryRLIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusionRetina200727441942517420692
   PubMed Web of Science ®Google Scholar
• EpsteinDLAlgverePVvon WendtGSeregardSKvantaABenefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized studyOphthalmology2012119122587259122902212
   PubMed Web of Science ®Google Scholar
• HikichiTHiguchiMMatsushitaTTwo-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusionBr J Ophthalmol201498219519924215032
   PubMed Web of Science ®Google Scholar
• GregoriNZFeuerWRosenfeldPJNovel method for analyzing Snellen visual acuity measurementsRetina20103071046105020559157
   PubMed Web of Science ®Google Scholar
• Snellen - logMAR Visual Acuity Calculator Available from: http://www.myvisiontest.com/logmar.php
   Google Scholar
• NarayananRPanchalBDasTChhablaniJJalaliSAliMHMARVEL Study GroupA randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report 1Br J Ophthalmol1282015
   Web of Science ®Google Scholar
• BrynskovTKempHSørensenTLIntravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practiceRetina20143481637164324646663
   PubMed Web of Science ®Google Scholar
• PacellaEPacellaFLa TorreGTesting the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatmentClin Ther20121636e413e422
   Google Scholar
• ChakravarthyUHardingSPRogersCAIVAN Study InvestigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trialLancet201338299001258126723870813
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGFineSLRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• Ruiz-MorenoJMAriasLMonteroJACarneiroASilvaRIntravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathological myopia: 4-year outcome (with CATT and IVAN)Br J Ophthalmol201397111447145024026146
   PubMed Web of Science ®Google Scholar
• NepomucenoABTakakiEPaes de AlmeidaFPA prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edemaAm J Ophthalmol20131563502510.e223795985
   PubMed Web of Science ®Google Scholar
• FordJAEldersAShyangdanDRoylePWaughNThe relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review (with IVAN and CATT)BMJ2012345e518222890029
   PubMed Web of Science ®Google Scholar
• Retinopathy Clinical Research NetworkWellsJAGlassmanARAyalaARComparative effectiveness randomized clinical trial of aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, protocol TN Engl J Med20153721193120325692915
   PubMed Web of Science ®Google Scholar
• BergKPedersenTRSandvikLBragadóttirRComparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocolOphthalmology2015122114615225227499
   PubMed Web of Science ®Google Scholar
• DeCroosFCTodorichBAlshareefRNeovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective reviewJ Ophthalmic Vis Res20149446146825709772
   PubMedGoogle Scholar